Advertisement

Supraesophageal Reflux Disease (SERD)

  • Timna NaftaliEmail author
Chapter

Abstract

Supraesophareal reflux disease is a form of acid reflux manifested not by heartburn but rather by respiratory or laryngeal symptoms. It is caused by reflux of acidic gastric contents into the larynx. Esophagoscopy is usually normal, but inspection of the larynx may reveal signs such as edema or erythema. Conventional pH monitoring is not sensitive enough to detect reflux to the upper esophagus, but the yield is improved with the combination of impedance monitoring (MII) with pH monitoring. Other possible diagnostic methods are the Dx–pH measurement system that measures aerosolized droplets of acid in the oropharynx, and salivary pepsin that can be used as a diagnostic marker. These methods, however, are not commonly available. Lifestyle modifications may improve the symptoms but the backbone of therapy is proton pump inhibitors. A therapeutic trial of proton pump inhibitor twice daily for 2 months is usually enough to produce symptomatic improvement. Some carefully selected patients may also benefit from anti-reflux surgery. Due to the nonspecific nature of the symptoms and the difficulty in diagnosis it is accepted that failure of a properly administered therapeutic trial should prompt further investigation for another diagnosis.

Keywords

Reflux laryngitis Multichannel intraluminal impedance and pH (MII-pH) monitoring Extraesophageal manifestation of GERD Laryngopharyngeal reflux PPI Reflux finding score Reflux symptom index Dx–pH 

References

  1. 1.
    Richter JE, Friedenberg F. Gastroesophageal reflux disease. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtrans gastrointestinal and liver disease. 9th ed. Philadelphia: Saunders; 2010.Google Scholar
  2. 2.
    Kim KY, Kim GH, Kim DU, et al. Is ineffective esophageal motility associated with gastropharyngeal reflux disease? World J Gastroenterol. 2008;14(39):6030–5. doi: 10.3748/wjg.14.6030.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lin GG, Scott JG. Prevention of esophagopharyngeal reflux by augmenting the upper esophageal sphincter pressure. Laryngoscope. 2014;124(10):2268–74. doi: 10.1016/j.pestbp.2011.02.012.Investigations. CrossRefGoogle Scholar
  4. 4.
    Babaei A, Venu M, Naini SR, et al. Impaired upper esophageal sphincter reflexes in patients with Supraesophageal reflux disease. Gastroenterology. 2015;149(6):1381–91. doi: 10.1053/j.gastro.2015.07.007.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Passàli D, Caruso G, Passàli FM. ENT manifestations of gastroesophageal reflux. Curr Allergy Asthma Rep. 2008;8(3):240–4. doi: 10.1007/s11882-008-0040-8.CrossRefPubMedGoogle Scholar
  7. 7.
    Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111(8):1313–7. doi: 10.1097/​00005537-200108000-00001.
  8. 8.
    Ozturan O, Dogan R, Yenigun A, Veyseller B, Yildrim YS. Photographic objective alterations for Laryngopharyngeal reflux diagnosis. J Voice. 2017;31(1):78–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Vaezi MF, Schroeder PL, Richter JE. Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. Am J Gastroentero. 1997;92:825–9.Google Scholar
  10. 10.
    Bardan E. Pharyngoesophageal pH monitoring. Am J Med. 2003;115(3 suppl. 1):3–5. doi: 10.1016/S0002–9343(03)00202-X.Google Scholar
  11. 11.
    Tutuian R, Castell DO. Use of multichannel intraluminal impedance to document proximal esophageal and pharyngeal nonacidic reflux episodes. Am J Med. 2003;115(3 suppl. 1):119S–23S. doi: 10.1016/S0002–9343(03)00209-2.CrossRefPubMedGoogle Scholar
  12. 12.
    Wan Y, Yan Y, Ma F, et al. LPR: how different diagnostic tools shape the outcomes of treatment. J Voice. 2014;28(3):362–8. doi: 10.1016/j.jvoice.2013.12.004.CrossRefPubMedGoogle Scholar
  13. 13.
    Chiou E, Rosen R, Nurko S. Effect of different pH criteria on dual-sensor pH monitoring in the evaluation of supraesophageal gastric reflux in children. J Pediatr Gastroenterol Nutr. 2011;52(4):399–403. doi: 10.1097/MPG.0b013e3181ef378b.CrossRefPubMedGoogle Scholar
  14. 14.
    Dulery C, Lechot A, Roman S, et al. A study with pharyngeal and esophageal 24-hour pH-impedance monitoring in patients with laryngopharyngeal symptoms refractory to proton pump inhibitors. Neurogastroenterol Motil. 2017;29(1):1–8. doi: 10.1111/nmo.12909.CrossRefGoogle Scholar
  15. 15.
    Wiener GJ, Tsukashima R, Kelly C, et al. Oropharyngeal pH monitoring for the detection of liquid and aerosolized supraesophageal gastric reflux. J Voice. 2009;23(4):498–504. doi: 10.1016/j.jvoice.2007.12.005.CrossRefPubMedGoogle Scholar
  16. 16.
    Yadlapati R, Pandolfino JE, Lidder AK, Shabeeb N, Jaiyeola DM, Adkins C, Agrawal N, Cooper A, Price CP, Ciolino JD, Gawron AJ, Smith SS, Bove M, Tan BK. Oropharyngeal pH testing does not predict response to proton pump inhibitor therapy in patients with laryngeal symptoms. Am J Gastroenterol. 2016;111(11):1517–24.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Spyridoulias A, Lillie S, Vyas A, Fowler SJ. Detecting laryngopharyngeal reflux in patients with upper airways symptoms: symptoms, signs or salivary pepsin? Respir Med. 2015;109(8):963–9. doi: 10.1016/j.rmed.2015.05.019.CrossRefPubMedGoogle Scholar
  18. 18.
    McGlashan JA, Johnstone LM, Sykes J, et al. The value of a liquid alginate suspension (Gaviscon advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2009;266:243–51.CrossRefPubMedGoogle Scholar
  19. 19.
    Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.Google Scholar
  20. 20.
    Richter JE. Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. Am J Med. 2003;115(3 Suppl. 1):179S–87S. doi: 10.1016/S0002–9343(03)00221-3.CrossRefPubMedGoogle Scholar
  21. 21.
    Ogawa M, Hosokawa K, Iwahashi T, Inohara H. The results of Kaplan-Meier and multivariate analyses of etiological factors related to the outcome of combined pharmacological therapy against laryngeal granuloma. Acta Otolaryngol. 2016;6489:1–6. doi: 10.1080/00016489.2016.1193891.Google Scholar
  22. 22.
    Yuksel ES, Vaezi MF. Therapeutic strategies for laryngeal manifestations of gastroesophageal reflux disease. J Clin Gastroenterol. 2013;47(3):195–204. doi: 10.1097/MCG.0b013e31827458f9.CrossRefPubMedGoogle Scholar
  23. 23.
    Watson G, O’Hara J, Carding P, et al. TOPPITS: trial of proton pump inhibitors in throat symptoms. Study protocol for a randomised controlled trial. Trials. 2016;17(1):175. doi: 10.1186/s13063-016-1267-7. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Vaezi MF, Lopez R, Hicks D, Abelson T, et al. What is the optimal initial therapy duration for patients with suspected GERD-related laryngitis? Gastroenterology. 2006;130:A140.Google Scholar
  25. 25.
    Sahin M, Vardar R, Ersin S, Kirazli T, Ogut MF, Akyildiz NS, Bor S. The effect of antireflux surgery on laryngeal symptoms, findings and voice parameters. Eur Arch Otorhinolaryngol. 2015;272(11):3375–83.CrossRefPubMedGoogle Scholar
  26. 26.
    So JBY, Zeitels SM, Rattner DW. Outcome of atypical symptoms attributed to gastresophageal reflux disease treated by laparoscopic fundoplication. Surgery. 1998;124:28–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Gastroenterology and Liver DiseaseMeir HospitalKfar SabaIsrael
  2. 2.Sackler School of Medicine, Tel Aviv UniversityTel AvivIsrael

Personalised recommendations